Oramed Pharmaceuticals ORMP
NASDAQ ORMP
$4.13 +0.16 (+4.03%)
At close: Nov 11, 2026 · 4:00 PM EST

Oramed Pharmaceuticals (ORMP) Gains from Equity Investments (2020)

Updated

Oramed Pharmaceuticals' Gains from Equity Investments came in at $1 million for Q1 2021.

Analysis

Oramed Pharmaceuticals (ORMP) Gains from Equity Investments (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Oramed Pharmaceuticals 164.02 Mn -170.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2020 1.00 Mn
API Access

Oramed Pharmaceuticals Gains from Equity Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=ORMP&period=max&api_key=YOUR_API_KEY